Clearpoint Neuro Inc logo

Clearpoint Neuro Inc(CLPT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$8.48
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CLPT

11/13/2026: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.

ClearPoint Neuro Inc is a medical technology company specializing in real-time MRI-guided navigation hardware, software, and disposables for neurological and spine procedures. The company's primary business strengths lie in its proprietary navigation platform and expanding partnerships with biopharmaceutical firms developing targeted cell and gene therapies. Its main growth opportunity centers on the increasing clinical adoption of minimally invasive neurosurgery and potential commercial approvals of partner drug pipelines. Key risks include persistent net losses, hospital capital spending constraints, and intense competition from larger medical device incumbents. The stock suits growth-oriented investors willing to accept volatility in exchange for exposure to advanced neuro-technology innovations, while monitoring ongoing cash burn and partner clinical trial milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitClearPoint offers strong top-line revenue growth potential driven by expanding neurosurgery procedures and innovative gene therapy delivery partnerships.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp upside movements following positive clinical trial readouts or strong quarterly earnings beats.
Value investorWeak fitThe company is currently unprofitable and trades at high price-to-sales ratios without near-term earnings or book value safety margins.
Dividend investorWeak fitClearPoint pays no dividends and retains all capital to fund ongoing growth and operational expansion.
Low-risk investorWeak fitSmall-cap medical device volatility, negative earnings, and execution risks create high volatility unsuited for risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings due to its small market capitalization and reaction to clinical or financial news.
Valuation riskMedium / highValuation relies heavily on long-term future growth expectations rather than current positive earnings.
Competition risk (large medtech incumbents)HighWell-capitalized competitors like Medtronic possess vastly larger sales channels and bundled product offerings.
Business qualityMediumProprietary technology and sticky hospital relationships indicate strong product quality, offset by lack of net profitability.
Dividend incomeLow / noneThe company does not distribute income to shareholders.
Execution riskHighSuccess depends on successfully commercializing new products and scaling biopharma partnerships on schedule.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 271.82M USD
Price to earnings Ratio -
1Y Target Price 21.5
Price to earnings Ratio -
1Y Target Price 21.5
Volume (30-day avg) 688.0K shares
Beta 1.36
52 Weeks Range 8.27 - 19.63
Updated Date 11/15/2026
52 Weeks Range 8.27 - 19.63
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -4.2%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CLPT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
CLPT has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+17.8%) is partially offset by negative earnings growth (-35.0%), weak cash generation (FCF margin -66.1%), weak profitability (net margin -69.1%).

Financial Health Rating

★★★★★
CLPT's financial health is soft, with the relatively strongest area being solid liquidity, including working-capital and asset support (WC/assets 54.1%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CLPT's strongest growth driver at +17.8% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-35.0%, negative) and free-cash-flow growth (-165.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 51.7% and approximately 81.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.92% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 7.42%
Mak Capital One LLC 7.41%
Vanguard Capital Management, LLC 3.85%
State Street Corp 2.55%
Geode Capital Management, LLC 2.34%

Unit Economics (Per $1K Revenue)

★★★★★
CLPT generates approximately $614 of gross profit, $-654 of operating income, and $-661 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.22% (Tax Credit)

Quantitative Style Profile

★★★★★
CLPT has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Capital EquipmentSales and leasing of hardware navigation systems and software licenses to hospitals and medical centers.Provides the initial footprint in surgical suites, unlocking future recurring disposable sales.
Disposables and ServicesSingle-use sterile procedural kits, head frames, cannulas, and related clinical support services.Acts as the recurring revenue engine that scales directly with hospital procedure volumes.
Bipharma Partner ServicesPre-clinical development, consulting, and navigation support for pharmaceutical companies testing gene therapies.Offers high-value upside if partner drugs gain regulatory approval and commercial traction.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 12.11
Enterprise Value 299.34M
Price to Sales(TTM) 5.97
Enterprise Value 299.34M
Price to Sales(TTM) 5.97
Enterprise Value to Revenue 6.58
Enterprise Value to EBITDA -7.07
Shares Outstanding 32.05M
Shares Floating 26.12M
Shares Outstanding 32.05M
Shares Floating 26.12M
Percent Insiders 6.92
Percent Institutions 51.67

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.